Guillain–Barré and Miller Fisher syndromes—new diagnostic classification

  • A Corrigendum to this article was published on 07 October 2014


Guillain–Barré syndrome (GBS) and its variant, Miller Fisher syndrome (MFS), exist as several clinical subtypes with different neurological features and presentations. Although the typical clinical features of GBS and MFS are well recognized, current classification systems do not comprehensively describe the full spectrum of either syndrome. In this Perspectives article, GBS and MFS are classified on the basis of current understanding of the common pathophysiological profiles of each disease phenotype. GBS is subclassified into classic and localized forms (for example, pharyngeal–cervical–brachial weakness and bifacial weakness with paraesthesias), and MFS is divided into incomplete (for example, acute ophthalmoparesis, acute ataxic neuropathy) and CNS subtypes (Bickerstaff brainstem encephalitis). Diagnostic criteria based on clinical characteristics are suggested for each condition. We believe this approach to be more inclusive than existing systems, and argue that it could facilitate early clinical diagnosis and initiation of appropriate immunotherapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 07 October 2014

    In Box 1 of the originally published article, Jong Seok Bae should have been included as a member of the GBS Classification Group. Also, in Table 2, the row title 'Bifacial weakness with distal paraesthesias' should have read 'Bifacial weakness with paraesthesias'. These errors have been corrected in the HTML and PDF versions of the article.


  1. 1

    Guillain, G., Barré, J. A. & Strohl, A. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des réflexes tendineux [French]. Bull. Mem. Hop. Paris 40, 1462–1470 (1916).

  2. 2

    Guillain, G. Les polyradiculonévrites avec dissociation alumbinocytologique et á evolution favorable (syndrome de Guillain et Barré) [French]. J. Belge Neurol. Psychiatr. 38, 323–329 (1938).

  3. 3

    Fisher, M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med. 255, 57–65 (1956).

  4. 4

    Bickerstaff, E. R. Brain-stem encephalitis: further observations on a grave syndrome with benign prognosis. Br. Med. J. 1, 1384–1387 (1957).

  5. 5

    Asbury, A. K., Arnason, B. G., Karp, H. R. & McFarlin, D. E. Criteria for diagnosis of Guillain–Barré syndrome. Ann. Neurol. 3, 565–566 (1978).

  6. 6

    Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann. Neurol. 27 (Suppl.), S21–S24 (1990).

  7. 7

    Ropper, A. H. Unusual clinical variants and signs in Guillain–Barré syndrome. Arch. Neurol. 43, 1150–1152 (1986).

  8. 8

    Ropper, A. H. Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal–cervical–brachial weakness. Arch. Neurol. 51, 671–675 (1994).

  9. 9

    Ropper, A. H., Wijdicks, E. F. M. & Truax, B. Guillain–Barré Syndrome (F. A. Davis, 1990).

  10. 10

    van der Meché, F. G. et al. Diagnostic and classification criteria for the Guillain–Barré syndrome. Eur. Neurol. 45, 133–139 (2001).

  11. 11

    Sejvar, J. J. et al. Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599–612 (2011).

  12. 12

    Wakerley, B. R. & Yuki, N. Pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry 85, 339–344 (2013).

  13. 13

    Richter, R. B. The ataxic form of polyradiculoneuritis (Landry–Guillain–Barré syndrome): clinical and pathologic observations. J. Neuropathol. Exp. Neurol. 21, 171–184 (1962).

  14. 14

    Kimoto, K. et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 67, 1837–1843 (2006).

  15. 15

    Mizoguchi, K. et al. Two species of antiganglioside antibodies in a patient with a pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry 57, 1121–1123 (1994).

  16. 16

    Miura, Y., Susuki, K., Yuki, N., Ayabe, M. & Shoji, H. Guillain–Barré syndrome presenting pharyngeal–cervical–brachial weakness in the recovery phase. Eur. Neurol. 48, 53–54 (2002).

  17. 17

    Koike, H. et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 133, 2881–2896 (2010).

  18. 18

    Koike, H. et al. The spectrum of clinicopathological features in pure autonomic neuropathy. J. Neurol. 259, 2067–2075 (2012).

  19. 19

    Ohyama, K. et al. Autonomic manifestations in acute sensory ataxic neuropathy: a case report. Auton. Neurosci. 179, 155–158 (2013).

  20. 20

    Uncini, A. & Yuki, N. Sensory Guillain–Barré syndrome and related disorders: an attempt at systematization. Muscle Nerve 45, 464–470 (2012).

  21. 21

    Pan, C. L., Yuki, N., Koga, M., Chiang, M. C. & Hsieh, S. T. Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody. Neurology 57, 1316–1318 (2001).

  22. 22

    Yuki, N., Odaka, M. & Hirata, K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features. Ophthalmology 108, 196–200 (2001).

  23. 23

    Kokubun, N. et al. Conduction block in acute motor axonal neuropathy. Brain 133, 2897–2908 (2010).

  24. 24

    Arai, M., Susuki, K. & Koga, M. Axonal pharyngeal–cervical–brachial variant of Guillain–Barré syndrome without anti-GT1a IgG antibody. Muscle Nerve 28, 246–250 (2003).

  25. 25

    Nagashima, T. et al. Paraparetic Guillain–Barré syndrome: extending the axonal spectrum. Neurol. Clin. Neurosci. 1, 224–226 (2013).

  26. 26

    Umapathi, T., Tan, E. Y., Kokubun, N., Verma, K. & Yuki, N. Non-demyelinating, reversible conduction failure in Fisher syndrome and related disorders. J. Neurol. Neurosurg. Psychiatry 83, 941–948 (2012).

  27. 27

    Susuki, K., Koga, M., Hirata, K., Isogai, E. & Yuki, N. A Guillain–Barré syndrome variant with prominent facial diplegia. J. Neurol. 256, 1899–1905 (2009).

  28. 28

    Uncini, A., Susuki, K. & Yuki, N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin. Neurophysiol. 124, 1928–1934 (2013).

  29. 29

    Shahrizaila, N. & Yuki, N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J. Neurol. Neurosurg. Psychiatry 84, 576–583 (2013).

  30. 30

    Ito, M. et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J. Neurol. 255, 674–682 (2008).

  31. 31

    Chiba, A., Kusunoki, S., Obata, H., Machinami, R. & Kanazawa, I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology 43, 1911–1917 (1993).

  32. 32

    Liu, J. X., Willison, H. J. & Pedrosa-Domellof, F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest. Ophthalmol. Vis. Sci. 50, 3226–3232 (2009).

  33. 33

    Ito, M., Matsuno, K., Sakumoto, Y., Hirata, K. & Yuki, N. Ataxic Guillain–Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J. Neurol. Neurosurg. Psychiatry 82, 294–299 (2011).

  34. 34

    Jindal, G., Parmar, V. R. & Gupta, V. K. Isolated ptosis as acute ophthalmoplegia without ataxia, positive for anti-GQ1b immunoglobulin G. Pediatr. Neurol. 41, 451–452 (2009).

  35. 35

    Yuki, N., Koga, M. & Hirata, K. Isolated internal ophthalmoplegia associated with immunoglobulin G anti-GQ1b antibody. Neurology 51, 1515–1516 (1998).

  36. 36

    Yuki, N., Susuki, K. & Hirata, K. Ataxic Guillain–Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology 54, 1851–1853 (2000).

  37. 37

    Yuki, N. & Uncini, A. Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve 49, 629–635 (2014).

  38. 38

    Notturno, F., Caporale, C. M. & Uncini, A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve 37, 265–268 (2008).

  39. 39

    Willison, H. J., Almemar, A., Veitch, J. & Thrush, D. Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides. Neurology 44, 2395–2397 (1994).

  40. 40

    Koga, M., Yoshino, H., Morimatsu, M. & Yuki, N. Anti-GT1a IgG in Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry 72, 767–771 (2002).

  41. 41

    Nagashima, T., Koga, M., Odaka, M., Hirata, K. & Yuki, N. Continuous spectrum of pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. Arch. Neurol. 64, 1519–1523 (2007).

  42. 42

    O'Leary, C. P. et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neurol. Neurosurg. Psychiatry 61, 649–651 (1996).

  43. 43

    Ogawara, K. et al. Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann. Neurol. 48, 624–631 (2000).

  44. 44

    McKhann, G. M. et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 33, 333–342 (1993).

  45. 45

    Yuki, N. et al. Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes. J. Neurol. 259, 1181–1190 (2012).

  46. 46

    Jackson, C. E., Barohn, R. J. & Mendell, J. R. Acute paralytic syndrome in three American men: comparison with Chinese cases. Arch. Neurol. 50, 732–735 (1993).

  47. 47

    Yuki, N. & Hirata, K. Preserved tendon reflexes in Campylobacter neuropathy. Ann. Neurol. 43, 546–547 (1998).

  48. 48

    Kuwabara, S. et al. Hyperreflexia in axonal Guillain–Barré syndrome subsequent to Campylobacter jejuni enteritis. J. Neurol. Sci. 199, 89–92 (2002).

  49. 49

    Fokke, C. et al. Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria. Brain 137, 33–43 (2014).

  50. 50

    Baheti, N. N., Manuel, D., Shinde, P. D., Radhakrishnan, A. & Nair, M. Hyperreflexic Guillain–Barré syndrome. Ann. Indian Acad. Neurol. 13, 305–307 (2010).

  51. 51

    Nishimoto, Y., Odaka, M., Hirata, K. & Yuki, N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J. Neuroimmunol. 148, 200–205 (2004).

  52. 52

    Uncini, A., Manzoli, C., Notturno, F. & Capasso, M. Pitfalls in electrodiagnosis of Guillain–Barré syndrome subtypes. J. Neurol. Neurosurg. Psychiatry 81, 1157–1163 (2010).

  53. 53

    An ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41, 617–618 (1991).

  54. 54

    Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J. Peripher. Nerv. Syst. 15, 1–9 (2010).

  55. 55

    Rajabally, Y. A., Nicolas, G., Pieret, F., Bouche, P. & Van den Bergh, P. Y. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J. Neurol. Neurosurg. Psychiatry 80, 1364–1368 (2009).

  56. 56

    Ichikawa, H. et al. Unilateral oculomotor nerve palsy associated with anti-GQ1b IgG antibody. Neurology 59, 957–958 (2002).

  57. 57

    Logullo, F., Manicone, M., Di Bella, P. & Provinciali, L. Asymmetric Guillain–Barré syndrome. Neurol. Sci. 27, 355–359 (2006).

  58. 58

    Susuki, K., Yuki, N., Muramatsu, M. & Hirata, K. Unilateral ophthalmoparesis and limb ataxia associated with anti-GQ1b IgG antibody. J. Neurol. 247, 652–653 (2000).

  59. 59

    Ruts, L., van Koningsveld, R. & van Doorn, P. A. Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations. Neurology 65, 138–140 (2005).

  60. 60

    Kuitwaard, K., van Koningsveld, R., Ruts, L., Jacobs, B. C. & van Doorn, P. A. Recurrent Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry 80, 56–59 (2009).

  61. 61

    Mossberg, N. et al. The recurrent Guillain–Barré syndrome: a long-term population-based study. Acta Neurol. Scand. 126, 154–161 (2012).

  62. 62

    Ropper, A. H. The Guillain–Barré syndrome. N. Engl. J. Med. 326, 1130–1136 (1992).

  63. 63

    Nagashima, T., Odaka, M., Koga, M., Yuki, N. & Hirata, K. A case of pharyngeal–cervical–brachial weakness suggestive of the nosological continuity between acute oropharyngeal palsy [Japanese]. Rinsho Shinkeigaku 42, 523–526 (2002).

  64. 64

    Bickerstaff, E. R. & Cloake, P. C. Mesencephalitis and rhombencephalitis. Br. Med. J. 2, 77–81 (1951).

  65. 65

    Odaka, M. et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain–Barré syndrome. Brain 126, 2279–2290 (2003).

  66. 66

    Wakerley, B. R., Soon, D., Chan, Y. C. & Yuki, N. Atypical Bickerstaff brainstem encephalitis: ataxic hypersomnolence without ophthalmoplegia. J. Neurol. Neurosurg. Psychiatry 84, 1206–1207 (2013).

  67. 67

    Lin, J. J. et al. Clinical variants of Guillain–Barré syndrome in children. Pediatr. Neurol. 47, 91–96 (2012).

  68. 68

    Ropper, A. H. & Samuels, M. A. Adam's and Victor's Principle of Neurology 9th edn 1251–1325 (McGraw–Hill, 2009).

  69. 69

    Sakakibara, R. et al. Prevalence and mechanism of bladder dysfunction in Guillain–Barré syndrome. Neurourol. Urodyn. 28, 432–437 (2009).

  70. 70

    Yanagihara, N., Mori, H., Kozawa, T., Nakamura, K. & Kita, M. Bell's palsy. Nonrecurrent v recurrent and unilateral v bilateral. Arch. Otolaryngol. 110, 374–377 (1984).

Download references


The authors are grateful to James Sejvar for his suggestions and critical reading of the manuscript. The authors' work was supported by the Singapore National Medical Research Council (Individual Research Grant 10nov086 and Clinician Science Award 047/2012 to N.Y.) and Yong Loo Lin School of Medicine, Singapore (R-172-000-264-733).

Author information





B.R.W. and N.Y. researched data for the article and contributed equally to writing the article. B.R.W., A.U., N.Y. and all members of the GBS Classification Group made substantial contributions to discussions of the content, and review and/or editing of the manuscript before submission.

Corresponding author

Correspondence to Nobuhiro Yuki.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wakerley, B., Uncini, A., Yuki, N. et al. Guillain–Barré and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol 10, 537–544 (2014).

Download citation

Further reading